Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044120 | 1.00 | CA1 (0.45) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13413134 | 1.00 | CA1 (0.45) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13413131 | 0.90 | CA1 (0.45) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL9675593 | 0.88 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL9676521 | 0.88 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL10978956 | 0.86 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL8534469 | 0.85 | CA1 (0.40) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13114385 | 0.85 | FOLH1 (0.33) | — | |
| SCHEMBL3374209 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL8270762 | 0.83 | CA1 (0.39) | CA1CA2CA7CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919021-B2 | Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions | IBET—INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA (PT) | 2018-03-20 | — | — | US | disclosed |
| US-20170296618-A1 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS | IBET - INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA (PT) | 2017-10-19 | — | — | US | disclosed |
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| EP-1194449-B1 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MED RES FOUND (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7678760-B2 | Inhibitors of Memapsin 2 and use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-03-16 | — | — | US | disclosed |
| US-7244708-B2 | Inhibitors of memapsin 2 and use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1496124-A1 | Catalytically active recombinant memapsin and methods of use thereof | Oklahoma Medical Research Foundation (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040220079-A1 | COMPLEXING MEMAPSIN 2 IN PRESENCE OF ASPARTIC RESIDUES; DIAGNOSIS, THERAPY FOR ALZHEIMER'S DISEASE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| US-20030092629-A1 | Inhibitors of memapsin 2 and use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-05-15 | — | — | US | disclosed |
| US-6545127-B1 | Alzheimer*s disease; amyloid precursor protein | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-04-08 | — | — | US | disclosed |
| US-20020164760-A1 | Catalytically active recombinant memapsin and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2002-11-07 | — | — | US | disclosed |
| WO-2001000665-A9 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MED RES FOUND (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1194449-A2 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | Oklahoma Medical Research Foundation (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001000665-A2 | INHIBITORS OF MEMAPSIN 2 AND USE THEREOF | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE2, BACE1, PSEN2 | CA1 785/4885CA2 2737/4885CA7 4230/4885 |
| US-20030092629-A1 | Inhibitors of memapsin 2 and use thereof | MMEL1, MME, METAP2 | CA1 104/4885CA2 641/4885CA7 1360/4885 |
| US-20170296618-A1 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS | BACE1, BACE2, APP | CA1 920/4885CA2 3608/4885CA7 4148/4885 |
| US-20040220079-A1 | COMPLEXING MEMAPSIN 2 IN PRESENCE OF ASPARTIC RESIDUES; DIAGNOSIS, THERAPY FOR ALZHEIMER'S DISEASE | PSEN2, ANPEP, APP | CA1 1213/4885CA2 2292/4885CA7 4029/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | CA1 554/4885CA2 2853/4885CA7 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.